Investigative approaches to drug therapy

Scleroderma: From Pathogenesis to Comprehensive Management

Volumn , Issue , 2012, Pages 603-613

  Ong, Voon H ^a   Denton, Christopher P ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

B cells; Cell trafficking; Endothelin receptor antagonists; Epigenetic; Hmg coa reductase inhibitors; Immunosuppression; Peroxisome proliferator activated receptor; Phosphodiesterase type v inhibitor; T regulatory subsets; Tyrosine kinase

Indexed keywords

EID: 84906325926     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-5774-0_50     Document Type: Chapter

References (91)

1. Shand L, Lunt M, Nihtyanova S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis:application of a latent linear trajectory model. Arthritis Rheum. 2007;56(7):2422-31.
2. Nihtyanova SI, Tang EC, Coghlan JG, et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM. 2010;103:109-15.
3. Quillinan NP, Denton CP. Disease-modifying treatment in systemic sclerosis: current status. Curr Opin Rheumatol. 2009;21(6):636-41.
4. Rodriguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J, et al. Th17 polarization in systemic sclerosis is influenced by immunosuppressive treatment regardless time of evolution [abstract]. Arthritis Rheum. 2009;60(Suppl):420.
5. Radstake TR, van Bon L, Broen J, Hussiani A, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One. 2009;4(6):e5903.
6. Sundrud MS, Koralov SB, Feuerer M, et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science. 2009;324(5932):1334-8.
7. Pines M, Snyder D, Yarkoni S, et al. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant. 2003;9(7):417-25.
8. Kalogerou A, Gelou E, Mountantonakis S, et al. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis. 2005;64(8):1233-5.
9. Yellin M, Paliienko I, Balanescu A, et al. A phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA) [abstract]. Arthritis Rheum. 2009;60(Suppl 10):414.
10. Nishimura M, Kuboi Y, Muramoto K, et al. Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann NY Acad Sci. 2009;1173:350-6.
11. Cipriani P, Franca Milia A, Liakouli V, Pacini A, et al. Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications. Arthritis Rheum. 2006;54(9):3022-33.
12. Cipriani P, Guiducci S, Miniati I, Cinelli M, et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum. 2007;56(6):1994-2004.
13. Campioni D, Lo Monaco A, Lanza F, Moretti S, Ferrari L, et al. CXCR4 pos circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral blood of patients affected by systemic sclerosis. Haematologica. 2008;93(8):1233-7.
14. Keeley EC, Mehrad B, Strieter RM. Fibrocytes: bringing new insights into mechanisms of inflammation and fibrosis. Int J Biochem Cell Biol. 2010;42:535-42.
15. Phillips RJ, Burdick MD, Hong K, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004;114:438-46.
16. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA. 2003;100:8407-11.
17. Brooks WH, Le Dantec C, Pers JO, et al. Epigenetics and autoimmunity. J Autoimmun.. 2010;34:J207-19.
18. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 2006;54(7):2271-9.
19. Ghosh AK, Varga J. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol. 2007;213:663-71.
20. Huber LC, Distler JH, Moritz F, et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycininduced skin fibrosis. Arthritis Rheum. 2007;56:2755-64.
21. Hemmatazad H, Rodrigues HM, Maurer B, et al. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis Rheum. 2009;60(5):1519-29.
22. Garber K. HDAC inhibitors overcome first hurdle. Nat Biotechnol. 2007;25(1):17-9.
23. Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology (Oxford). 2010;49:583-7.
24. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger Jr TA, Morganti A, Kramer F, Korn JH, Seibold JR. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32-8.
25. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50(12):3985-93.
26. García de la Peña-Lefebvre P, Rodríguez Rubio S, Valero Expósito M, Carmona L, et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology (Oxford). 2008;47(4):464-6.
27. Penn H, Black CM, Denton CP. An open label trial of the endothelin receptor antagonist bosentan in scleroderma renal crisis (BIRD-1) [abstract]. Arthritis Rheum. 2009;60(Suppl 10):451.
28. Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005;112(19):2980-5.
29. Herrick AL, van den Hoogen F, Gabrielli A. Nihad, modified-release sildenafil reduces Raynaud's attack frequency in systemic sclerosis [abstract]. Arthritis Rheum. 2009;60(Suppl 10):472.
30. Brueckner CS, Becker MO, Kroencke T, et al. Effect of sildenafil on digital ulcers in systemic sclerosis-analysis from a single centre pilot study. Ann Rheum Dis. 2010;69:1475-8.
31. Agarwal V, Ghosh P, Sharma A, Bhakuni D, Kumar S, Singh U, Vijayvergiya R, Yadav M, Laishram G, Ghosh A, Majhi B, Mukherjee D, Islam S, Kapoor A. Efficacy of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study [abstract]. Arthritis Rheum. 2010;62(Suppl 10):2086.
32. Kuwana M, Okazaki Y, Kaburaki J. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis registry [abstract]. Arthritis Rheum. 2009;60(Suppl 10):448.
33. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost. 2006;95:49-55.
34. Louneva N, Huaman G, Fertala J, Jimenez SA. Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum. 2006;54:1298-308.
35. Moriyama T, Kawada N, Nagatoya K, Takeji M, Horio M, Ando A, Imai E, Hori M. Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int. 2001;59(6):2095-103.
36. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, Quinones MA, Zoghbi WA, Entman ML, Roberts R, Marian AJ. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation. 2001;104(3):317-24.
37. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black CM, Abraham D. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest. 2001;108(2):241-50.
38. Carulli MT, Handler C, Coghlan JG, Black CM, Denton CP. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis? Ann Rheum Dis. 2008;67(1):105-9.
39. Zhu Y, Liu Y, Zhou W, Xiang R, Jiang L, Huang K, Xiao Y, Guo Z, Gao J. A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. Respir Res. 2010;11:34.
40. Yoshizaki A, Yanaba K, Yoshizaki A, Iwata Y, Komura K, Ogawa F, Takenaka M, Shimizu K, Asano Y, Hasegawa M, Fujimoto M, Sato S. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum. 2010;62(8):2476-87.
41. Magro L, Mohty M, Catteau B, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood. 2009;114:719-22.
42. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58(8):2543-8.
43. Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011;70:1003-9.
44. Pope J, McBain D, Petrlich L, et al. A proof of concept trial of Gleevec (Imatinib) in active diffuse scleroderma [abstract]. Arthritis Rheum. 2009;60(Suppl 10):608.
45. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908-16.
46. Distler O, Distler JH, Varga J, Denton CP, Lafyatis R, Wigley F, Schett G, Matucci-Cerinic M, Wright T, Bertolino A, Gergely P. A multicenter, open-label, proof of concept study of imatinib mesylate demonstrates no benefit for the treatment of fibrosis in patients with early, diffuse systemic sclerosis. Arthritis Rheum. 2010;62(Suppl 10):560.
47. Denton CP, Nihtyanova SI, Varga J, Distler O, Wigley FM, Lafyatis R, Distler JH, Schett G, Matucci-Cerinic M, Wright T, Antunes M, Racine A, Bertolino A, Gergely Jr P. Comparative analysis of change in modified Rodnan Skin score in patients with diffuse systemic sclerosis receiving imatinib mesylate suggests similar disease course to matched patients receiving standard therapy. Arthritis Rheum. 2010;62(Suppl 10):566.
48. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator activated receptor-gamma. Am J Pathol. 2009;174:519-33.
49. Kapoor M, McCann M, Liu S, et al. Loss of PPARg in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum. 2009;60:2822-9.
50. Harris TE, Lawrence Jr JC. TOR signaling. Sci STKE. 2003;2003(212):re15.
51. Shegogue D, Trojanowska M. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem. 2004;279:23166-75.
52. Mazereeuw-Hautier J, Gres S, Fanguin M, Cariven C, Fauvel J, Perret B, Chap H, Salles JP, Saulnier-Blache JS. Production of lysophosphatidic acid in blister fluid: involvement of a lysophospholipase D activity. J Invest Dermatol. 2005;125(3):421-7.
53. Bridle KR, Popa C, Morgan ML, Sobbe AL, Clouston AD, Fletcher LM, et al. Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transpl. 2009;15:1315-24.
54. Wang S, Wilkes MC, Leof EB, Hirschberg R. Noncanonical TGF-β pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol. 2009;298:F142-9.
55. Yoon KH. Proliferation signal inhibitors for the treatment of refractory autoimmune rheumatic diseases: a new therapeutic option. Ann N Y Acad Sci. 2009;1173:752-6.
56. Fried L, Kirsner RS, Bhandarkar S, Arbiser JL. Efficacy of rapamycin in scleroderma: a case study. Lymphat Res Biol. 2008;6(3-4):217-9.
57. Buschhausen L, Kamm M, Arns W, Schulze-Lohoff E, Weber M. Successful treatment of a severe case of idiopathic pulmonary fibrosis with rapamycin. Med Klin (Munich). 2005;100(3):161-4.
58. Su TI, Khanna D, Furst DE, et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum. 2009;60(12):3821-30.
59. Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 2007;56(1):323-33.
60. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002;4(Suppl 3):S233-42.
61. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1 from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest. 1999;103:1253-60.
62. Moodley YP, Scaffidi AK, Misso NL, Keerthisingam C, McAnulty RJ, Laurent GJ, Mutsaers SE, Thompson PJ, Knight DA. Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation. Am J Pathol. 2003;163(1):345-54.
63. Ghazizadeh M, Tosa M, Shimizu H, Hyakusoku H, Kawanami O. Functional implications of the IL-6 signaling pathway in keloid pathogenesis. J Invest Dermatol. 2007;127(1):98-105.
64. Luckett LR, Gallucci RM. Interleukin-6 (IL-6) modulates migration and matrix metalloproteinase function in dermal fibroblasts from IL-6KO mice. Br J Dermatol. 2007;156(6):1163-71.
65. Ong V, Nihtyanova S, Black CM, et al. A clinically defined subset of dcSSc is associated with elevated serum IL-6 level [abstract]. Arthritis Rheum. 2009;60(Suppl):440.
66. Linterman MA, Vinuesa CG. Signals that influence T follicular helper cell differentiation and function. Semin Immunopathol. 2010;32(2):183-96.
67. Pradère JP, Klein J, Grès S, Guigné C, Neau E, Valet P, Calise D, Chun J, Bascands JL, Saulnier-Blache JS, Schanstra JP. LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol. 2007;18(12):3110-8.
68. Tokumura A, Carbone LD, Yoshioka Y, Morishige J, Kikuchi M, Postlethwaite A, Watsky MA. Elevated serum levels of arachidonoyllysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci. 2009;6(4):168-76.
69. Balazs L, Okolicany J, Ferrebee M, Tolley B, Tigyi G. Topical application of the phospholipid growth factor lysophosphatidic acid promotes wound healing in vivo. Am J Physiol Regul Integr Comp Physiol. 2001;280(2):R466-72.
70. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, Polosukhin V, Wain J, Karimi-Shah BA, Kim ND, Hart WK, Pardo A, Blackwell TS, Xu Y, Chun J, Luster AD. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008;14(1):45-54.
71. Swaney JS, Chapman C, Correa LD, Stebbins KJ, Broadhead AR, Bain G, Santini AM, Darlington J, King CD, Baccei CS, Lee C, Parr TA, Roppe JR, Seiders TJ, Ziff J, Prasit P, Hutchinson JH, Evans JF, Lorrain DS. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011;336(3):693-700.
72. Svejda B, Kidd M, Giovinazzo F, Eltawil K, Gustafsson BI, Pfragner R, Modlin IM. The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment. Cancer. 2010;116(12):2902-12.
73. Ruddell RG, Oakley F, Hussain Z, Yeung I, Bryan-Lluka LJ, Ramm GA, Mann DA. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol. 2006;169(3):861-76.
74. Dees C, Akhmetshina A, Busch N, Zwerina J, Bader M, Schett G, et al. Platelet derived serotonin (5-HT) plays a crucial role for experimental fibrosis [abstract]. Arthritis Rheum. 2009;60(Suppl 10):1063.
75. Königshoff M, Dumitrascu R, Udalov S, Amarie OV, Reiter R, Grimminger F, Seeger W, Schermuly RT, Eickelberg O. Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention. Thorax. 2010;65(11):949-55.
76. Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001;40(9):1038-43.
77. Marcos E, Fadel E, Sanchez O, Humbert M, Dartevelle P, Simonneau G, Hamon M, Adnot S, Eddahibi S. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res. 2004;94(9):1263-70.
78. Akhmetshina A, Dees C, Pileckyte M, Szucs G, Spriewald BM, Zwerina J, Distler O, Schett G, Distler JH. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum. 2008;58(8):2553-64.
79. Nagatoya K, Moriyama T, Kawada N, Takeji M, Oseto S, Murozono T, Ando A, Imai E, Hori M. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int. 2002;61(5):1684-95.
80. Skhirtladze C, Distler O, Dees C, Akhmetshina A, Busch N, Venalis P, Zwerina J, Spriewald B, Pileckyte M, Schett G, Distler JH. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum. 2008;58(5):1475-84.
81. Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jüngel A, Zwerina J, Gay S, Schett G, Distler O, Distler JH. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008;22(7):2214-22.
82. Maurer B, Busch N, Jüngel A, Gay R, Schett G, Michel B, Gay S, Distler J, Distler O. Tyrosine kinase inhibitors (TKI) are promising therapeutic agents for the proliferative vasculopathy in SSc [abstract]. Arthritis Rheum. 2009;60(Suppl 10):1263.
83. Pilling D, Tucker NM, Gomer RH. Aggregated IgG inhibits the differentiation of human fibrocytes. J Leukoc Biol. 2006;79(6):1242-51.
84. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;363(14):1303-12.
85. Williams W, Scherle P, Shi J, Newton R, McKeever E, Fridman J, Burn T, Vaddi K, Levy R, Moreland L. A randomized placebo-controlled study of INCB018424, a selective Janus Kinase1& 2 (JAK1&2) inhibitor in rheumatoid arthritis (RA). Arthritis Rheum. 2008;58:S431.
86. Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, Kucine N, Gardner JR, Combs AP, Vaddi K, Haley PJ, Burn TC, Rupar M, Bromberg JF, Heaney ML, de Stanchina E, Fridman JS, Levine RL. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood. 2010;115(14):2919-27.
87. Abou-Raya A, Abou-Raya S, Helmii M. Statins as immunomodulators in systemic sclerosis. Ann N Y Acad Sci. 2007;1110:670-80.
88. Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol. 2008;35:1801-8.
89. Shi-wen X, Eastwood M, Stratton RJ, Denton CP, Leask A, Abraham DJ. Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology (Oxford). 2010;49(2):259-63.
90. Castelino FV, Seiders J, Bain G, Brooks SF, King C, Swaney JS, Lorrain DS, Chun J, Luster AD, Tager AM. Genetic deletion or pharmacologic antagonism of LPA(1) ameliorates dermal fibrosis in a scleroderma mouse model. Arthritis Rheum. 2011. doi: 10.1002/art.30262.
91. Fang X, Yu S, LaPushin R, Lu Y, Furui T, Penn LZ, Stokoe D, Erickson JR, Bast RC Jr, Mills GB. Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J. 2000;352 Pt 1:135-43.